| WO2006053625A1 | 2006-05-26 | |||
| WO1998045299A1 | 1998-10-15 |
| BE897864A | 1984-03-29 | |||
| EP1812449A1 | 2007-08-01 | |||
| EP1546155A2 | 2005-06-29 |
| CLAIMS: 1. Salts shown with Formula II; Formula II wherein A stands for Q-Cis primary, secondary and/or tertiary amine comprising at least one hydroxy group. 2. A compound according to claim 1, wherein A is selected from ethanolamine, 1-deoxy-l- methylamino-sorbitol, isopropanolamine, 1-deoxy-l-methylamino-D-glucitol- (2S,4R)-4- Hydroxy proline, tris(hydroxymethyl)aminomethane, N-(Tri(hydroxymethyl)methyl)glycine, thiamine, 2-methyl-aminophenol, N,N-Bis(2-hydroxyethyl)glycine. 3. A salt according to claim 1, wherein said salt is used in solid and liquid pharmaceutical dosage forms. 4. A solid dosage form according to claim 3 which is suitable for oral, buccal, sublingual application. 5. A dosage form according to claim 3 and 4 which is in the form of film coated tablets, extended release tablets, modified release tablets, chewable tablets, effervescent tablets, effervescent granules, suspensions, water dispersible tablets, water dispersible granules. 6. A pharmaceutical composition according to claim 3 and 5 wherein said composition comprises the salts according to claim 1 in an amount equivalent to 1-4000 mg of cefdinir. 7. A pharmaceutical composition according to any of the preceding claims indicated for use in treatment of infections caused by gram positive and gram negative bacteria. 8. A salt according to claim 1 which is in amorphous or crystal form. 9. A process for preperation of the salts according to claim 1 comprising the steps of; a) Dissolving cefdinir and an organic amine comprising more than one hydroxy group in a suitable solvent and stirring said solution at a temperature in the range of 0-100 °C b) Separation of the the product that precipitates upon cooling of the reaction mixture, and optionally c) Purification of the obtained product. 10. A process according to claim 9 wherein the amine comprising at least one hydroxy group can be selected from a group comprising; ethanolamine, isopropanolamine, 1-deoxy-l- methylamino-sorbitol, 1 -deoxy- 1 -methylamino-D-glucitol, (2S,4R)-4-hydroxyproline, tris(hydroxymethyl)aminomethane, N-(tri(hydroxymethyl)methyl)glycine, thiamine, 2- methyl aminophenol, N,N-Bis(2-hydroxyethyl)glycine. 11. A process according to claim 9 wherein the solvent used in said process can be selected from a group comprising polar, non-polar, aprotic, protic organic solvents, water and/or a combination of these. 12. A process according to claim 9 wherein the solvent used in said process can be selected from a group comprising water, ethanol, methanol, isopropanol, dimethylformamide, dimethylsulfoxide, methylenechloride, tetrahydrofuran, toluene, acetonitrile, hexane, heptane, diethylether, benzene, ethyl acetate, acetone, t-butyl alcohol, t-butyl methyl ether, chloroform, cyclohexane, 1 ,2-dichloroethane, 1 ,2-dimethoxyethane, dioxane, methyl ethyl ketone, ethylene glycol, 2-propanol, pyridine, triethylamine. 13. A process according to claim 9 wherein the reaction is carried out at a temperature of 0-100 °C, preferably at e temperature of 10-70 °C, more preferably at a temperature of 20 - 60 °C. 14. A process according to claim 9, wherein the product can be separated from the reaction mixture by any one of the methods comprising extraction, filtration and/or evaporation of the solvent. 15. A process according to claim 9 wherein said product can be purified by use of the techniques such as extraction, recrystallization by solvent, recrystallization by activated charcoal, all chromatographic techniques, distillation, filtration alone or in a combined form. 16. Cefdinir salt shown with Formula III 17. Cefdinir salt shown with Formula IV Formula IV 18. A pharmaceutical composition wherein during the production or use of said pharmaceutical composition organic amine salts according to claim 1-17 forms. |
Present invention relates to pharmaceutically acceptable salts of cefdinir, specifically to primary, secondary and tertiary amine salts of cefdinir, preparation methods and pharmaceutical compositions comprising them.
Cefdinir molecule which is shown with Formula I was first disclosed in the patent numbered BE897864 and its chemical name is (6R,7R)-7-[[(2Z)-(2-amino-4- thiazolyl)(hydroxyimino)acetyl] amino]-3-ethenyl-8-oxo-5-thia- 1 -azabicyclo[4.2.0]oct-2-en-2- carboxylic acid. This molecule which is a third generation cephalosporin, is indicated for the treatment of several illnesses caused by gram positive and gram negative bacteria.
Formula I
Although in vitro tests prove that cefdinir is a highly potent antibiotic, the bioavailability of the finished product is less than expected and manufacturers experience problems while developing formulations due to its poor solubility in water, methanol, ethanol, acetone and many other organic solvents.
Subject matter of the present invention is related to the development of water soluble derivatives of cefdinir without losing its antibiotic effect and to prepare pharmaceutical dosage forms comprising these derivatives.
Detailed description of the invention
Present invention relates to organic amine salts of cefdinir, wherein said organic amines comprise at least one hydroxy group and relates to pharmaceutical dosage forms comprising said cefdinir salts.
The patent numbered EP1812449 discloses ammonium salt of cefdinir which can be used for the preparation cefdinir monohydrate. Another patent EP1546155, discloses ammonium and organic amine salts of cefdinir and use of these molecules as intermediates for synthesis of cefdinir.
As seen from these examples, prior art examples generally deal with the methods related to synthesis of cefdinir instead of its solubility problem. Accordingly, present invention relates to the salts shown with the general Formula II.
Formula II
The group shown with "A" in Formula II is a CI -CI 5 primary, secondary and/or tertiary amine characterized by containing at least one hydroxy group. Said amine can be selected from but not limited with a group comprising; ethanolamine, isopropanolamine, 1-deoxy-l-methylamino- sorbitol, 1-deoxy-lmethylamino-D-glucitol, tris(hydroxymethyl)aminomethane, N- (tri(hydroxymethyl)methyl)glycine, N,N-Bis(2-hydroxyethylglycine), 2-methyl aminophenol, (2S,4R)-4-Hydroxy proline, thiamine.
In another aspect, one of the preferred molecules according to the present invention is the cefdinir salt shown with Formula III.
In another aspect, one of the preferred molecules according to the present invention cefdinir salt shown with Formula IV.
ormu a
Inventors have found that cefdinir salts of the present invention have better water solubility compared to cefdinir in free base form and amine salts of cefdinir that do not comprise a hydroxy group which are known from the prior art. In general, salts shown with Formula II are obtained with conventional techniques known from the prior art.
In another aspect present invention relates to use of the amine salts of cefdinir according to the present invention in solid and liquid dosage forms.
In another aspect present invention relates to use of the amine salts of cefdinir according to the present invention in dosage forms suitable for oral, buccal, sublingual application.
In another aspect present invention relates to use of the amine salts of cefdinir according to the present invention in pharmaceutical formulations in the form of film tablets, extended release tablets, modified release tablets, chewable tablets, effervescent tablets, effervescent granules, water dispersible tablet, water dispersible granules.
Amine salts of the present invention that is used in said pharmaceutical compositions can be in amorphous or crystal form.
In another aspect present invention relates to use of amine salts of cefdinir according to present invention in amounts equivalent to 1 -4000 mg cefdinir.
In another aspect present invention relates to use of amine salts of cefdinir according to present invention and pharmaceutical compositions comprising them for the treatment of infections caused by gram positive and gram negative bacteria.
Molecules according to the present invention can be prepared according to but not limited with the examples given below.
Example 1: Preparation of Tris(hydroxymethyl)aminomethane salt of cefdinir
39.5 g of cefdinir (0.1 mol) and 18.7 g tris(hydroxymethyl)aminomethane (0.15 mol) is stirred in a mixture of 100 mL ethanol and 50 mL deionized water at a temperature of 25-35 °C. The reaction mixture is then cooled to the room temperature and the formed precipitate is separated and recrystallized.
Example 2: Preparation of 1-Deoxy-l-methylamino-sorbitol salt of cefdinir
39.5 g cefdinir (0.1 mol) and 58.6 g 1-Deoxy-l-methylamino-sorbitol (0.3 mol)is stirred in 100 mL of methanol at a temperature of 40 °C. The reaction mixture is cooled in a cooler and the precipitate that forms is filtrated right away and purified by washing with cold methanol. In all stages of the preparation of the molecules of invention; all the known polar, non-polar, protic and aprotic organic solvents and water, all the known purification methods such as extraction, recrystallization with solvent/anti-solvent, recrystallization with activated carbon, chromatographic techniques, distillation and filtration can be used.
In another aspect, molecules of invention can form during the manufacture or use of a pharmaceutical composition comprising cefdinir and an amine comprising more than one hydroxy group.
Solvent that can be used for the preparation and purification of the molecules of invention can be choson from but not limited with a group comprising; water, ethanol, methanol, isopropanol, dimethylformamide, dimethylsulfoxide, methylenechloride, tetrahydrofuran, toluene, acetonitrile, hexane, heptane, diethylether, benzene, ethyl acetate, acetone, t-butyl alcohol, t- butyl methyl ether, chloroform, cyclohexane, 1 ,2-dichloroethane, 1 ,2-dimethoxyethane, dioxane, ethyl methyl ketone, ethylene glycol, 2-propanol, pyridine, triethylamine.